{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:49:17Z","timestamp":1790470157520,"version":"4.1.0"},"reference-count":103,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T00:00:00Z","timestamp":1457308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Currently, physicians treating chronic myeloid leukaemia (<jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>) patients can rely on a wide spectrum of therapeutic options: the best use of such options is essential to achieve excellent clinical outcomes and, possibly, treatment\u2010free remission (<jats:styled-content style=\"fixed-case\">TFR<\/jats:styled-content>). To accomplish this, proper integration of expert clinical and laboratory monitoring of <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content> patients is fundamental. Molecular response (<jats:styled-content style=\"fixed-case\">MR<\/jats:styled-content>) monitoring of patients at defined time points has emerged as an important success factor for optimal disease management and <jats:italic><jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ABL<\/jats:styled-content>1<\/jats:italic> kinase domain mutation screening is useful to guide therapeutic reassessment in patients who do not achieve optimal responses to tyrosine kinase inhibitor therapy. Deeper <jats:styled-content style=\"fixed-case\">MR<\/jats:styled-content>s might be associated with improved long\u2010term survival outcomes. More importantly, they are considered a gateway to <jats:styled-content style=\"fixed-case\">TFR<\/jats:styled-content>. In molecular biology, novel procedures and technologies are continually being developed. More sophisticated molecular tools and automated analytical solutions are emerging as <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content> treatment endpoints and expectations become more and more ambitious. Here we provide a critical overview of current and novel methodologies, present their strengths and pitfalls and discuss what their present and future role might be.<\/jats:p>","DOI":"10.1111\/bjh.13966","type":"journal-article","created":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T09:58:44Z","timestamp":1457344724000},"page":"337-349","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Present and future of molecular monitoring in chronic myeloid leukaemia"],"prefix":"10.1111","volume":"173","author":[{"given":"Simona","family":"Soverini","sequence":"first","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine Haematology\/Oncology \u201cL. e A. Ser\u00e0gnoli\u201d University of Bologna Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"De Benedittis","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine Haematology\/Oncology \u201cL. e A. Ser\u00e0gnoli\u201d University of Bologna Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Mancini","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine Haematology\/Oncology \u201cL. e A. Ser\u00e0gnoli\u201d University of Bologna Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine Haematology\/Oncology \u201cL. e A. Ser\u00e0gnoli\u201d University of Bologna Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,7]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000334716"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08071.x"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-553X.2010.01236.x"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2014.10.002"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403136"},{"key":"e_1_2_11_8_1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood.V124.21.1809.1809","article-title":"Evaluation of Cepheid Xpert\u00ae BCR\u2010ABL monitor assay in three Italian reference centers for monitoring of BCR\u2010ABL transcript levels in CML patients","volume":"124","author":"Bochicchio M.T.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_11_9_1","first-page":"59","article-title":"An Italian multicentric evaluation of the Q\u2010LAMP technology applied to the molecular detection of BCR\u2010ABL transcripts in archived RNA from Philadelphia positive onset samples","volume":"100","author":"Bochicchio M.T.","year":"2015","journal-title":"Haematologica"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1179\/2295333715Y.0000000009"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.974047"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-150680"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.5217"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.03.011"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13108"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu490"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.034389"},{"key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood.V124.21.152.152","article-title":"Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) trial (DASISION, CA180\u2010056)","volume":"124","author":"Cortes J.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.04.001"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.104"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.29"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2012.08.001"},{"key":"e_1_2_11_23_1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.5858\/2007-131-947-QAOTBT","article-title":"Quantitative assessment of the BCR\u2010ABL transcript using the Cepheid Xpert BCR\u2010ABL Monitor assay","volume":"131","author":"Dufresne S.D.","year":"2007","journal-title":"Archives of Pathology and Laboratory Medicine"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.095158"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23560"},{"key":"e_1_2_11_26_1","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1182\/blood.V124.21.4540.4540","article-title":"Exceeding MR5.0 sensitivity in routine BCR\u2010ABL1 analysis using multiplex digital PCR","volume":"124","author":"Fredslund Andersen R.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403135"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr060"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02582-10"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.555569"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01723-13"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2013.03.003"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.11.027"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.129221"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.85"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.9020"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12423"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1053\/shem.2003.50044"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0092"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8230"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-510396"},{"key":"e_1_2_11_43_1","first-page":"236","article-title":"ENESTnd 5\u2010year follow\u2010up: continued benefit of frontline nilotinib compared with imatinib in patients with chronic myeloid leukemia in chronic phase","volume":"99","author":"Hughes T.","year":"2014","journal-title":"Haematologica"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.02.005"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490128"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2013.10.007"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2007.060112"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.36"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.11.030"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12187"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03951.x"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.155"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1468-4"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1845-6"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1988"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.151.151"},{"key":"e_1_2_11_59_1","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.V124.21.1792.1792","article-title":"A comparison of droplet digital PCR and quantitative RT\u2010PCR for low level BCR\u2010ABL in CML patients with molecular responses","volume":"124","author":"Maier J.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-407486"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20568"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2009.080150"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.07.029"},{"key":"e_1_2_11_64_1","first-page":"979","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation","volume":"90","author":"Merante S.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2011.176198"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24120"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.168"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214221"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-10-296"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/28.12.e63"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23238"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.06187"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1112"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401393"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-010-0801-z"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.116"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011239"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5797"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532341"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1186\/gm191"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-255109"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1516"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-197186"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326405"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.09.011"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-487728"},{"key":"e_1_2_11_88_1","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood.V122.21.3824.3824","article-title":"Sensitivity, reproducibility and clinical utility of next\u2010generation sequencing (NGS) for BCR\u2010ABL1 kinase domain mutation screening: results from the CML Work Package of the IRON\u2010II (Interlaboratory RObustness Of Next\u2010Generation Sequencing) International Study","volume":"122","author":"Soverini S.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_11_89_1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood.V122.21.380.380","article-title":"Ultra deep sequencing (UDS) allows more sensitive detection of tyrosine kinase inhibitor (TKI)\u2010resistant BCR\u2010ABL mutations that would influence therapeutic decision at the time of switchover to second\u2010 or third\u2010line therapy","volume":"122","author":"Soverini S.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncoscience.114"},{"key":"e_1_2_11_91_1","first-page":"444","article-title":"Quantitation of targets for PCR by use of limiting dilution","volume":"13","author":"Sykes P.J.","year":"1992","journal-title":"BioTechniques"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.056853"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.06.018"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1437"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.2144\/000113733"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802043903"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.16.9236"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbs044"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-291641"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2012.196477"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.217"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2007.085472"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-011-0328-x"},{"key":"e_1_2_11_104_1","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.V87.6.2588.bloodjournal8762588","article-title":"Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation","volume":"87","author":"Zhang J.G.","year":"1996","journal-title":"Blood"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13966","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T13:10:26Z","timestamp":1696252226000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,7]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1111\/bjh.13966"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13966","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,7]]},"assertion":[{"value":"2016-03-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}